Citius Pharmaceuticals Stock Book Value Per Share
CTXR Stock | USD 0.75 0.02 2.60% |
Citius Pharmaceuticals fundamentals help investors to digest information that contributes to Citius Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Citius Stock. The fundamental analysis module provides a way to measure Citius Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Citius Pharmaceuticals stock.
Last Reported | Projected for Next Year | ||
Book Value Per Share | 0.54 | 1.02 | |
Tangible Book Value Per Share | 0.13 | 0.14 |
Citius | Book Value Per Share |
Citius Pharmaceuticals Company Book Value Per Share Analysis
Citius Pharmaceuticals' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Citius Pharmaceuticals Book Value Per Share | 0.53 X |
Most of Citius Pharmaceuticals' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Citius Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Citius Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Citius Pharmaceuticals is extremely important. It helps to project a fair market value of Citius Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Citius Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Citius Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Citius Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Competition |
Citius Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of Citius Pharmaceuticals is about 0.533 times. This is 131.35% lower than that of the Pharmaceuticals sector and 100.21% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.97% higher than that of the company.
Citius Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Citius Pharmaceuticals' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Citius Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Citius Pharmaceuticals by comparing valuation metrics of similar companies.Citius Pharmaceuticals is currently under evaluation in book value per share category among related companies.
Citius Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Citius Pharmaceuticals from analyzing Citius Pharmaceuticals' financial statements. These drivers represent accounts that assess Citius Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Citius Pharmaceuticals' important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 40.7M | 220.5M | 176.8M | 103.5M | 93.2M | 60.5M | |
Enterprise Value | 28.2M | 151.2M | 135.7M | 77.5M | 69.8M | 45.5M |
Citius Fundamentals
Return On Equity | -0.41 | ||||
Return On Asset | -0.23 | ||||
Current Valuation | 102.42 M | ||||
Shares Outstanding | 159.1 M | ||||
Shares Owned By Insiders | 7.73 % | ||||
Shares Owned By Institutions | 17.01 % | ||||
Number Of Shares Shorted | 12.43 M | ||||
Price To Earning | (1.34) X | ||||
Price To Book | 1.49 X | ||||
EBITDA | (36.54 M) | ||||
Net Income | (32.54 M) | ||||
Cash And Equivalents | 48.04 M | ||||
Cash Per Share | 0.33 X | ||||
Total Debt | 481.25 K | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 11.40 X | ||||
Book Value Per Share | 0.53 X | ||||
Cash Flow From Operations | (29.06 M) | ||||
Short Ratio | 20.27 X | ||||
Earnings Per Share | (0.26) X | ||||
Target Price | 5.33 | ||||
Number Of Employees | 22 | ||||
Beta | 1.51 | ||||
Market Capitalization | 121.74 M | ||||
Total Asset | 103.61 M | ||||
Retained Earnings | (162.23 M) | ||||
Working Capital | 28.59 M | ||||
Current Asset | 893 K | ||||
Current Liabilities | 5.18 M | ||||
Net Asset | 103.61 M |
About Citius Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Citius Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Citius Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Citius Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Citius Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Citius Stock
0.79 | DSGN | Design Therapeutics Financial Report 14th of May 2024 | PairCorr |
Moving against Citius Stock
0.54 | NVS | Novartis AG ADR Earnings Call This Week | PairCorr |
0.52 | BNR | Burning Rock BiotechLtd Financial Report 4th of June 2024 | PairCorr |
0.45 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
The ability to find closely correlated positions to Citius Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Pharmaceuticals to buy it.
The correlation of Citius Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Citius Pharmaceuticals Piotroski F Score and Citius Pharmaceuticals Altman Z Score analysis. To learn how to invest in Citius Stock, please use our How to Invest in Citius Pharmaceuticals guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Citius Stock analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Transaction History View history of all your transactions and understand their impact on performance | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is Citius Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Citius Pharmaceuticals. If investors know Citius will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Citius Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.26) | Return On Assets (0.23) | Return On Equity (0.41) |
The market value of Citius Pharmaceuticals is measured differently than its book value, which is the value of Citius that is recorded on the company's balance sheet. Investors also form their own opinion of Citius Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Citius Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Citius Pharmaceuticals' market value can be influenced by many factors that don't directly affect Citius Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Citius Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Citius Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Citius Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.